Document is current
Any future updates will be listed below
-
Authors
Singh, Neha Atulkumar
Graff-Radford, Jonathan
Machulda, Mary M.
Carlos, Arenn F.
Schwarz, Christopher G.
Senjem, Matthew L.
Jack, Clifford R. Jr.
Lowe, Val J.
Josephs, Keith A.
Whitwell, Jennifer L. https://orcid.org/0000-0001-6914-1563
-
Funding
Funding for this research was provided by:
National Institute of Health (R01-AG50603)
National Institutes of Health (R01-DC010367)
Alzheimer's Association (NIRG-12-242215)
- License Information
-
More Information
Article History
Received: 9 October 2023
Revised: 28 February 2024
Accepted: 1 March 2024
First Online: 29 March 2024
Declarations
:
: Dr. Singh and Dr. Carlos have no disclosures to report. Dr. Whitwell, Dr. Machulda, Dr. Schwarz, and Dr. Josephs reported receiving research funding from the NIH. Dr. Graff-Radford reported receiving research support from the NIH and he also serves as an editorial board member for Neurology. Matthew Senjem reported holding stock in Gilead Sciences, Inc., Inovio Pharmaceuticals, Medtronic, Oncothyreon, Inc., and PAREXEL International. Dr. Jack reported serving on an independent data monitoring board for Roche, has consulted for and served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR foundation and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. Dr. Lowe reported consulting for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receiving research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals and the NIH (NIA, NCI).
: The study was approved by the Mayo Clinic IRB.
: Informed consent was obtained from all patients to participate in this study.
